• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Rethinking to riluzole mechanism of action: the molecular link among protein kinase CK1δ activity, TDP-43 phosphorylation, and amyotrophic lateral sclerosis pharmacological treatment.

作者信息

Bissaro Maicol, Moro Stefano

机构信息

Molecular Modeling Section (MMS), Department of Pharmaceutical and Pharmacological Sciences, University of Padova, Padova, Italy.

出版信息

Neural Regen Res. 2019 Dec;14(12):2083-2085. doi: 10.4103/1673-5374.262578.

DOI:10.4103/1673-5374.262578
PMID:31397342
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6788255/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9992/6788255/496724ccc4f7/NRR-14-2083-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9992/6788255/496724ccc4f7/NRR-14-2083-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9992/6788255/496724ccc4f7/NRR-14-2083-g001.jpg

相似文献

1
Rethinking to riluzole mechanism of action: the molecular link among protein kinase CK1δ activity, TDP-43 phosphorylation, and amyotrophic lateral sclerosis pharmacological treatment.重新思考利鲁唑的作用机制：蛋白激酶CK1δ活性、TDP-43磷酸化与肌萎缩侧索硬化症药物治疗之间的分子联系。
Neural Regen Res. 2019 Dec;14(12):2083-2085. doi: 10.4103/1673-5374.262578.
2
Targeting Protein Kinase CK1δ with Riluzole: Could It Be One of the Possible Missing Bricks to Interpret Its Effect in the Treatment of ALS from a Molecular Point of View?以利鲁唑靶向蛋白激酶 CK1δ：从分子角度解释其在 ALS 治疗中作用的可能缺失环节之一？
ChemMedChem. 2018 Dec 20;13(24):2601-2605. doi: 10.1002/cmdc.201800632. Epub 2018 Nov 21.
3
Riluzole exerts central and peripheral modulating effects in amyotrophic lateral sclerosis.利鲁唑对肌萎缩侧索硬化症具有中枢和外周调节作用。
Brain. 2013 May;136(Pt 5):1361-70. doi: 10.1093/brain/awt085.
4
Safety and efficacy of rasagiline as an add-on therapy to riluzole in patients with amyotrophic lateral sclerosis: a randomised, double-blind, parallel-group, placebo-controlled, phase 2 trial.利鲁唑联用雷沙吉兰治疗肌萎缩侧索硬化症的安全性和有效性：一项随机、双盲、平行分组、安慰剂对照的 2 期临床试验。
Lancet Neurol. 2018 Aug;17(8):681-688. doi: 10.1016/S1474-4422(18)30176-5. Epub 2018 Jun 19.
5
Optimized 4,5-Diarylimidazoles as Potent/Selective Inhibitors of Protein Kinase CK1δ and Their Structural Relation to p38α MAPK.优化的4,5-二芳基咪唑作为蛋白激酶CK1δ的强效/选择性抑制剂及其与p38α丝裂原活化蛋白激酶的结构关系。
Molecules. 2017 Mar 24;22(4):522. doi: 10.3390/molecules22040522.
6
MTHFSD and DDX58 are novel RNA-binding proteins abnormally regulated in amyotrophic lateral sclerosis.MTHFSD 和 DDX58 是肌萎缩侧索硬化症中异常调节的新型 RNA 结合蛋白。
Brain. 2016 Jan;139(Pt 1):86-100. doi: 10.1093/brain/awv308. Epub 2015 Nov 2.
7
TDP-43 cytoplasmic inclusion formation is disrupted in -associated amyotrophic lateral sclerosis/frontotemporal lobar degeneration.TDP-43 细胞质包涵体的形成在与肌萎缩侧索硬化症/额颞叶痴呆相关的疾病中受到破坏。
Brain Commun. 2019;1(1):fcz014. doi: 10.1093/braincomms/fcz014. Epub 2019 Sep 11.
8
Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND).利鲁唑用于治疗肌萎缩侧索硬化症（ALS）/运动神经元病（MND）。
Cochrane Database Syst Rev. 2002(2):CD001447. doi: 10.1002/14651858.CD001447.
9
Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND).利鲁唑用于治疗肌萎缩侧索硬化症（ALS）/运动神经元病（MND）。
Amyotroph Lateral Scler Other Motor Neuron Disord. 2003 Sep;4(3):191-206.
10
Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND).利鲁唑用于治疗肌萎缩侧索硬化症（ALS）/运动神经元病（MND）。
Cochrane Database Syst Rev. 2007 Jan 24(1):CD001447. doi: 10.1002/14651858.CD001447.pub2.

引用本文的文献

1
ALS: A Silent Slayer of Motor Neurons. Traditional Chinese Herbal Medicine as an Effective Therapy.肌萎缩侧索硬化症：运动神经元的无声杀手。传统中药作为一种有效疗法。
Curr Pharm Des. 2025;31(17):1328-1346. doi: 10.2174/0113816128329141241205063352.
2
Hybrid derivatives containing dimethyl fumarate and benzothiazole scaffolds for the potential treatment of multiple sclerosis; in silico & in vivo study.含富马酸二甲酯和苯并噻唑支架的杂化衍生物，用于多发性硬化症的潜在治疗；体内外研究。
Daru. 2024 Dec;32(2):599-615. doi: 10.1007/s40199-024-00529-8. Epub 2024 Aug 6.
3
Assessing the efficacy of amyotrophic lateral sclerosis drugs in slowing disease progression: A literature review.

本文引用的文献

1
Targeting Protein Kinase CK1δ with Riluzole: Could It Be One of the Possible Missing Bricks to Interpret Its Effect in the Treatment of ALS from a Molecular Point of View?以利鲁唑靶向蛋白激酶 CK1δ：从分子角度解释其在 ALS 治疗中作用的可能缺失环节之一？
ChemMedChem. 2018 Dec 20;13(24):2601-2605. doi: 10.1002/cmdc.201800632. Epub 2018 Nov 21.
2
Riluzole, disease stage and survival in ALS.利鲁唑、肌萎缩侧索硬化症的疾病阶段与生存情况
Lancet Neurol. 2018 May;17(5):385-386. doi: 10.1016/S1474-4422(18)30091-7. Epub 2018 Mar 7.
3
EAAT2 and the Molecular Signature of Amyotrophic Lateral Sclerosis.
评估肌萎缩侧索硬化症药物在延缓疾病进展方面的疗效：一项文献综述。
AIMS Neurosci. 2024 Apr 30;11(2):166-177. doi: 10.3934/Neuroscience.2024010. eCollection 2024.
4
Protein aggregation and therapeutic strategies in SOD1- and TDP-43- linked ALS.与超氧化物歧化酶1（SOD1）和TDP - 43相关的肌萎缩侧索硬化症中的蛋白质聚集及治疗策略
Front Mol Biosci. 2024 May 24;11:1383453. doi: 10.3389/fmolb.2024.1383453. eCollection 2024.
5
Abnormal protein post-translational modifications induces aggregation and abnormal deposition of protein, mediating neurodegenerative diseases.异常的蛋白质翻译后修饰会诱导蛋白质聚集和异常沉积，介导神经退行性疾病。
Cell Biosci. 2024 Feb 12;14(1):22. doi: 10.1186/s13578-023-01189-y.
6
Exploring Advancements in the Treatment of Amyotrophic Lateral Sclerosis: A Comprehensive Review of Current Modalities and Future Prospects.探索肌萎缩侧索硬化症治疗的进展：当前治疗方式及未来前景的全面综述
Cureus. 2023 Sep 18;15(9):e45489. doi: 10.7759/cureus.45489. eCollection 2023 Sep.
7
An In Vivo Electroencephalographic Analysis of the Effect of Riluzole against Limbic and Absence Seizure and Comparison with Glutamate Antagonists.利鲁唑对边缘性发作和失神发作作用的体内脑电图分析及其与谷氨酸拮抗剂的比较
Pharmaceutics. 2023 Jul 22;15(7):2006. doi: 10.3390/pharmaceutics15072006.
8
Expanding the Toolbox: Novel Modulators of Endolysosomal Cation Channels.扩展工具箱：溶酶体阳离子通道的新型调节剂
Handb Exp Pharmacol. 2023;278:249-276. doi: 10.1007/164_2022_605.
9
Pharmacological Modulation of Glutamatergic and Neuroinflammatory Pathways in a Lafora Disease Mouse Model.拉福拉病小鼠模型中谷氨酸能和神经炎症途径的药物调节。
Mol Neurobiol. 2022 Oct;59(10):6018-6032. doi: 10.1007/s12035-022-02956-7. Epub 2022 Jul 14.
10
The Multifaceted Role of GPCRs in Amyotrophic Lateral Sclerosis: A New Therapeutic Perspective?GPCRs 在肌萎缩侧索硬化症中的多效性作用：一种新的治疗视角？
Int J Mol Sci. 2022 Apr 19;23(9):4504. doi: 10.3390/ijms23094504.
兴奋性氨基酸转运体2与肌萎缩侧索硬化症的分子特征
Adv Neurobiol. 2017;16:117-136. doi: 10.1007/978-3-319-55769-4_6.
4
Phosphorylation of TAR DNA-binding Protein of 43 kDa (TDP-43) by Truncated Casein Kinase 1δ Triggers Mislocalization and Accumulation of TDP-43.截短的酪蛋白激酶1δ对43千道尔顿TAR DNA结合蛋白（TDP-43）的磷酸化引发TDP-43的错误定位和积累。
J Biol Chem. 2016 Mar 11;291(11):5473-5483. doi: 10.1074/jbc.M115.695379. Epub 2016 Jan 14.
5
Protein kinase CK-1 inhibitors as new potential drugs for amyotrophic lateral sclerosis.蛋白激酶 CK-1 抑制剂作为肌萎缩性侧索硬化症的新型潜在药物。
J Med Chem. 2014 Mar 27;57(6):2755-72. doi: 10.1021/jm500065f. Epub 2014 Mar 12.
6
Riluzole, unlike the AMPA antagonist RPR119990, reduces motor impairment and partially prevents motoneuron death in the wobbler mouse, a model of neurodegenerative disease.与AMPA拮抗剂RPR119990不同，利鲁唑可减轻震颤小鼠（一种神经退行性疾病模型）的运动障碍，并部分预防运动神经元死亡。
Exp Neurol. 2006 Mar;198(1):114-28. doi: 10.1016/j.expneurol.2005.11.010. Epub 2006 Jan 4.
7
Pharmacological properties of benzazoles. I. Relationship between structure and paralyzing action.苯并唑类的药理性质。I. 结构与麻痹作用之间的关系。
J Pharmacol Exp Ther. 1952 Aug;105(4):486-97.
8
The pharmacology and mechanism of action of riluzole.利鲁唑的药理学及作用机制。
Neurology. 1996 Dec;47(6 Suppl 4):S233-41. doi: 10.1212/wnl.47.6_suppl_4.233s.
9
A controlled trial of riluzole in amyotrophic lateral sclerosis. ALS/Riluzole Study Group.利鲁唑治疗肌萎缩侧索硬化症的对照试验。肌萎缩侧索硬化症/利鲁唑研究组
N Engl J Med. 1994 Mar 3;330(9):585-91. doi: 10.1056/NEJM199403033300901.
10
2-Amino-6-trifluoromethoxy benzothiazole, a possible antagonist of excitatory amino acid neurotransmission--II. Biochemical properties.2-氨基-6-三氟甲氧基苯并噻唑，一种可能的兴奋性氨基酸神经传递拮抗剂——II. 生化特性
Neuropharmacology. 1985 Nov;24(11):1085-92. doi: 10.1016/0028-3908(85)90196-0.